Literature DB >> 32346835

Predictors of narcolepsy and hypersomnia due to medical disorder in pediatric craniopharyngioma.

Belinda N Mandrell1, Kayla LaRosa2, Donna Hancock3, Mary Caples3, April Sykes4, Zhaohua Lu4, Merrill S Wise5, Raja B Khan6, Thomas E Merchant7, Valerie McLaughlin-Crabtree2.   

Abstract

PURPOSE: Several studies describe sleep-wake disturbances in pediatric craniopharyngioma, but none have determined the prevalence or associated predictors of excessive sleepiness in this group after diagnosis and prior to post-operative observation or adjuvant radiotherapy. In this study, we report sleep-wake disturbances in children and adolescents with craniopharyngioma and associated clinical and treatment variables.
METHODS: After surgery and prior to radiotherapy or observation, pediatric patients (n = 110) with craniopharyngioma ≥ 3 years old completed a baseline sleep clinic evaluation by a pediatric sleep specialist, polysomnography (PSG) and next-day multiple sleep latency test (MSLT). MSLT was limited to those ≥ 6 years old. Logistic regression models were used to determine the relationship between patient characteristics and the presence and type of hypersomnia.
RESULTS: Amongst patients completing PSG and MSLT, 80% had polygraphic evidence of excessive daytime sleepiness. Hypersomnia due to medical condition was diagnosed in 45% and narcolepsy in 35%. Overweight or obese patients were more likely to be diagnosed with hypersomnia (P = 0.012) or narcolepsy (P = 0.009). Grade 2 hypothalamic involvement (HI) at diagnosis was associated with the diagnosis of narcolepsy (P = 0.0008).
CONCLUSIONS: This study describes the prevalence and associated predictors of hypersomnia for patients with craniopharyngioma after surgical resection. HI was predictive of narcolepsy diagnosis, and a higher body mass index z-score was associated with hypersomnia due to medical condition and narcolepsy. We recommend that sleep assessment and intervention begin after surgical resection, especially in overweight or obese patients and those with extensive tumors.

Entities:  

Keywords:  Hypersomnia; Hypothalamic involvement; Narcolepsy; Pediatric craniopharyngioma

Mesh:

Year:  2020        PMID: 32346835     DOI: 10.1007/s11060-020-03519-3

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  5 in total

Review 1.  Hypothalamic syndrome.

Authors:  Hermann L Müller; Maithé Tauber; Elizabeth A Lawson; Jale Özyurt; Brigitte Bison; Juan-Pedro Martinez-Barbera; Stephanie Puget; Thomas E Merchant; Hanneke M van Santen
Journal:  Nat Rev Dis Primers       Date:  2022-04-21       Impact factor: 52.329

2.  Sleep Disturbance and Its Association With Sluggish Cognitive Tempo and Attention in Pediatric Brain Tumor Survivors.

Authors:  Ineke M Olsthoorn; Alice Ann Holland; Raymond C Hawkins; Allen E Cornelius; Muhammad Usman Baig; Grace Yang; Daniel C Holland; Wafik Zaky; Peter L Stavinoha
Journal:  Front Neurosci       Date:  2022-06-23       Impact factor: 5.152

3.  Sleep Disturbances in Pediatric Craniopharyngioma: A Systematic Review.

Authors:  Ramona Cordani; Marco Veneruso; Flavia Napoli; Natascia Di Iorgi; Claudia Milanaccio; Alessandro Consales; Nicola Disma; Elisa De Grandis; Mohamad Maghnie; Lino Nobili
Journal:  Front Neurol       Date:  2022-05-13       Impact factor: 4.086

Review 4.  Sleep Disorders in Patients With Craniopharyngioma: A Physiopathological and Practical Update.

Authors:  Andrea Romigi; Tiziana Feola; Simone Cappellano; Michelangelo De Angelis; Giacomo Pio; Marco Caccamo; Federica Testa; Giuseppe Vitrani; Diego Centonze; Claudio Colonnese; Vincenzo Esposito; Marie-Lise Jaffrain-Rea
Journal:  Front Neurol       Date:  2022-02-09       Impact factor: 4.003

5.  Height, weight, and cardiovascular effects of stimulants on children with brain tumors.

Authors:  Raja B Khan; Maha Bano; Fang Wang; Pan Haitao; Anthony Christensen; Jessica Smith; Andrea Simmons; Zsila S Sadighi
Journal:  Pediatr Blood Cancer       Date:  2020-10-13       Impact factor: 3.167

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.